Ameriprise
STRO icon

Ameriprise’s Sutro Biopharma STRO Stock Holding History

Ameriprise’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.12M Buy
+244,669
New +$7.63M ﹤0.01% 2197
2025
Q1 		– Sell
-18,040
Closed -$332K – 4146
2024
Q4 		$332K Sell
18,040
-183
-1% -$5.59K ﹤0.01% 3686
2024
Q3 		$631K Buy
18,223
+83
+0.5% +$3.25K ﹤0.01% 3405
2024
Q2 		$532K Buy
18,140
+3,239
+22% +$128K ﹤0.01% 3395
2024
Q1 		$842K Buy
14,901
+1,777
+14% +$78.5K ﹤0.01% 3237
2023
Q4 		$563K Buy
13,124
+2,566
+24% +$81.4K ﹤0.01% 3415
2023
Q3 		$366K Sell
10,558
-2,002
-16% -$87.2K ﹤0.01% 3520
2023
Q2 		$584K Sell
12,560
-402
-3% -$20K ﹤0.01% 3380
2023
Q1 		$599K Buy
12,962
+4,746
+58% +$301K ﹤0.01% 3356
2022
Q4 		$664K Sell
8,216
-39
-0.5% -$2.71K ﹤0.01% 3300
2022
Q3 		$457K Buy
+8,255
New +$489K ﹤0.01% 3428

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Ameriprise's STRO Position: Q2 2026 in Review

Ameriprise opened a new position in Sutro Biopharma (STRO) in Q2 2026: 244,669 shares worth $8.12M. The stake represents ﹤0.01% of the portfolio and ranks #2197 among its holdings. This is a return to the name: Ameriprise previously reported a position in STRO as recently as Q4 2024.

Ameriprise first reported a position in STRO in Q3 2022 and has held it in 11 quarters since. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Ameriprise held 244,669 shares of Sutro Biopharma worth $8.12M as of Q2 2026.
  • Sutro Biopharma was a new Ameriprise position in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2197 holding.
  • Ameriprise first reported a position in Sutro Biopharma in Q3 2022 and has held it in 11 quarters since.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.